Intra-arterial Chemotherapy (IAC)
Treatment for Retinoblastoma
Typical Dosage: e.g., Melphalan 3-7.5 mg, Carboplatin 30-35 mg
Effectiveness
90%
Safety Score
25%
Clinical Trials
2
Participants
3K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
e.g., Melphalan 3-7.5 mg, Carboplatin 30-35 mg
Time to Effect
1 month
Treatment Duration
3-6 months
Evidence Quality
MODERATEConfidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$60,000
Side Effect Mgmt:$10,000
Total Annual:$85,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
18.5
Outcome-Based Costs
Cost per Responder
$97,143
Cost per Remission
$106,250
Comparison vs Systemic Chemotherapy
Cost Difference
+$10,000/year
More expensive
QALY Difference
+0.75 QALYs
Better outcomes
Dominance
No dominance
Intra-arterial Chemotherapy (IAC) Outcomes
for Retinoblastoma
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+88%
Remission Rate
+80%
Common Side Effects
Ocular/Orbital Complications
+30%
Myelosuppression (mild)
+20%
Femoral artery complications
+10%
Localized hair loss
+10%
Sources:
Active Clinical Trials
1 active trial recruiting for Intra-arterial Chemotherapy (IAC) in Retinoblastoma
Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome
NCT04681417RECRUITINGPHASE2, PHASE3
225 participants
INTERVENTIONAL
Saint-Denis, France +27 more
Started: Mar 25, 2021
Completed Clinical Trials
1 completed trial for Intra-arterial Chemotherapy (IAC) in Retinoblastoma
Intra-arterial Chemotherapy for Retinoblastoma
NCT04342572COMPLETEDPHASE1
5 participants
INTERVENTIONAL
St Louis, United States
Started: Aug 11, 2020